Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Keeping Patients in Mind: Noted Breast Cancer Researcher Pursues Broad Notion of Personalized Medicine

December 28th 2011

One of a small group of scientists who had a hand in developing Herceptin (trastuzumab) for the treatment of breast cancer, Dr. Debu Tripathy's current work is focused on understanding why some patients are resistant to the drug, and how to create more effective therapies for them.

Exploiting Oncogene Addiction and Immunogenicity May Be Path to Improved Results in HER2-Positive Breast Cancer

December 27th 2011

The approval of trastuzumab, targeted directly to the human epidermal growth factor receptor (HER2)-positive, was a major advance in extending the lives of women with HER2-positive breast cancer.

Dr. Vahdat Compares Halaven and Ixempra Neuropathy

December 22nd 2011

Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy

Dr. Perez Discusses the B-34 Clodronate Study

December 22nd 2011

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Florida, Discusses the B-34 Clodronate Study

Pharmacogenomics in Action: CYP2D6 Breast Cancer Debate Shows Intricacies of Genotyping

December 21st 2011

Recently reported and truly impressive clinical trial data have revealed the relevance of administering antineoplastic agents specifically and prospectively targeted to molecular abnormalities.

Adjuvant Zoledronic Acid May Improve Disease-Free Survival for Postmenopausal Women With Breast Cancer

December 15th 2011

A subanalysis of the AZURE study found that postmenopausal women had a disease-free survival advantage from the addition of zoledronic acid to their therapy.

Dr. Baselga Describes the Advantages of Dual Blockade

December 14th 2011

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

Dr. Perez Discusses the BOLERO-2 Everolimus Trial

December 14th 2011

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses the BOLERO-2 Everolimus Trial

Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival

December 9th 2011

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

December 9th 2011

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial

December 9th 2011

Dr. JosÃ© Baselga from Massachusetts General Hospital Discusses the CLEOPATRA Pertuzumab Trial

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

December 9th 2011

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

Dr. Tripathy on the AVEREL Bevacizumab Trial Results

December 9th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

December 9th 2011

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

December 8th 2011

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

December 8th 2011

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences

December 8th 2011

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

December 8th 2011

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial

The CLEOPATRA and BOLERO-2 Studies are Stirring Excitement at SABCS

December 7th 2011

The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.

Dr. Smith on the Brachytherapy Breast Cancer Trial

December 7th 2011

Dr. Benjamin Smith from MD Anderson Cancer Center Discusses the Brachytherapy Breast Cancer Trial